Ligand id: 7291

Name: ranolazine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ranolazine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 77.76
Molecular weight 427.25
XLogP 3.26
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used to treat chronic angina pectoris.
A Phase III clinical trial evaluating ranolazine in patients with incomplete revascularization post-PCI (percutaneous coronary intervention) is underway.
Mechanism Of Action and Pharmacodynamic Effects
The precise mechanism by which this drug works is unknown. However, ChEMBL lists the sodium channel type IV and V alpha subunits (SCN4A and SCN5A respectively) as the molecular targets of this drug. These proteins mediate voltage-dependent sodium ion permeability of excitable membranes [1]. SCN4A is also known as the skeletal muscle sodium channel isoform and SCN5A is known as the cardiac sodium channel isoform. So SCN5A is potentially responsible for the drug's cardiac effects.
External links